Drug Profile
Research programme: neurological disorder therapeutics - Eisai/University College London
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; University College London
- Class Antiparkinsonians
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Neurological-disorders in United Kingdom
- 12 Dec 2018 Early research in Neurological disorders is ongoing in United Kingdom
- 16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders in United Kingdom